Insider Trading & Ownership - Hillan Kenneth J.

Real time insider trading transaction history:

  • Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
  • Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
Time period
Insider Trading Transactions for Hillan Kenneth J.
Common stock purchase or sale:
Transaction
Date
Reported
DateTime
CompanySymbolInsider
Relationship
Shares
Traded
Average
Price
Total
Amount
Shares
Owned
Filing
2022-08-24
Sale
2022-08-25
5:00 pm
23andMe Holding Co.MEHillan Kenneth J.
Chief Therapeutics Officer
8,753$3.64$31,861196,083
(Direct)
View

Stock options: Exercise, Award, Grant, Conversion
Transaction
Date
Reported
DateTime
Exercisable
Expiration
CompanySymnbolInsider
Relationship
Shares
Traded
Conversion
Price
Shares
Owned
Filing
2023-12-07
Option Award
2023-12-08
5:17 pm
N/A
2033-12-06
Zymeworks Inc.ZYMEHillan Kenneth J.
Director
37,000$037,000
(Direct)
View
2023-06-05
Option Award
2023-06-07
4:20 pm
N/A
N/A
23andMe Holding Co.MEHillan Kenneth J.
Chief Therapeutics Officer
44,381$0221,876
(Direct)
View
2023-06-05
Tax Withholding
2023-06-07
4:20 pm
N/A
N/A
23andMe Holding Co.MEHillan Kenneth J.
Chief Therapeutics Officer
15,347$2.08221,876
(Direct)
View
2023-06-01
Option Award
2023-06-05
4:48 pm
N/A
2033-05-31
SANGAMO THERAPEUTICS INCSGMOHillan Kenneth J.
Director
41,650$077,350
(Direct)
View
2023-05-20
Tax Withholding
2023-05-23
4:05 pm
N/A
N/A
23andMe Holding Co.MEHillan Kenneth J.
Chief Therapeutics Officer
4,628$1.94192,842
(Direct)
View
2023-02-20
Tax Withholding
2023-02-22
5:12 pm
N/A
N/A
23andMe Holding Co.MEHillan Kenneth J.
Chief Therapeutics Officer
5,457$2.87191,705
(Direct)
View
2022-12-21
Option Award
2022-12-23
7:00 pm
N/A
2032-12-20
Zymeworks Inc.ZYMEHillan Kenneth J.
Director
25,000$025,000
(Direct)
View
2022-11-20
Tax Withholding
2022-11-22
4:11 pm
N/A
N/A
23andMe Holding Co.MEHillan Kenneth J.
Chief Therapeutics Officer
4,628$2.99197,162
(Direct)
View
2022-08-20
Tax Withholding
2022-08-22
6:12 pm
N/A
N/A
23andMe Holding Co.MEHillan Kenneth J.
Chief Therapeutics Officer
4,628$3.33204,836
(Direct)
View
2022-06-01
Tax Withholding
2022-06-02
4:26 pm
N/A
N/A
23andMe Holding Co.MEHillan Kenneth J.
Chief Therapeutics Officer
4,627$2.82209,464
(Direct)
View
2022-02-25
Option Award
2022-03-01
5:09 pm
N/A
2032-02-24
SANGAMO THERAPEUTICS INCSGMOHillan Kenneth J.
Director
37,500$060,700
(Direct)
View
2022-02-09
Option Award
2022-02-11
4:23 pm
N/A
2032-02-09
23andMe Holding Co.MEHillan Kenneth J.
Head of Therapeutics
685,504$0685,504
(Direct)
View

Ownership
2021-06-25
5:22 pm
N/A
2029-02-18
23andMe Holding Co.MEHillan Kenneth J.
Head of Therapeutics
0$02,018,452
(Direct)
View
2021-05-06
Option Award
2021-05-07
8:45 pm
N/A
2031-05-05
Zymeworks Inc.ZYMEHillan Kenneth J.
Director
9,000$09,000
(Direct)
View
2021-02-25
Option Award
2021-03-01
8:57 pm
N/A
2031-02-24
SANGAMO THERAPEUTICS INCSGMOHillan Kenneth J.
Director
24,600$039,600
(Direct)
View
2020-09-09
Option Award
2020-09-11
6:18 pm
N/A
2030-09-08
SANGAMO THERAPEUTICS INCSGMOHillan Kenneth J.
Director
45,000$045,000
(Direct)
View
2020-05-08
Option Award
2020-05-12
06:31 am
N/A
2030-05-07
Zymeworks Inc.ZYMEHillan Kenneth J.
Director
9,000$09,000
(Direct)
View
2019-05-06
Option Award
2019-05-08
4:23 pm
N/A
2029-05-05
Zymeworks Inc.ZYMEHillan Kenneth J.
Director
10,000$010,000
(Direct)
View